| 前收市價 | 8.59 |
| 開市 | 8.67 |
| 買盤 | 8.40 x 1100 |
| 賣出價 | 9.01 x 1000 |
| 今日波幅 | 8.43 - 8.89 |
| 52 週波幅 | 8.36 - 24.40 |
| 成交量 | |
| 平均成交量 | 952,391 |
| 市值 | 1.053B |
| Beta 值 (5 年，每月) | 1.38 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.82 |
| 業績公佈日 | 2023年11月01日 - 2023年11月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 24.95 |
Insider Monkey12 Best High Risk High Reward Stocks To Buy Now
In this piece, we will take a look at the 12 best high risk high reward stocks to buy now. If you want to skip our background on investing, then head on over to 5 Best High Risk High Reward Stocks To Buy Now. Investing is a risky endeavor, as is anything that involves the […]
Insider MonkeyAnalysts Are Upgrading These 10 Stocks
In this article, we will discuss the 10 stocks recently upgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts Are Upgrading These 5 Stocks. Although the equity markets have been buoyed by the expectation of lower interest rates this year, we may likely see an increase […]
BenzingaRelay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says
Raymond James initiated coverage of Relay Therapeutics Inc (NASDAQ: RLAY) with an Outperform rating and a price target of $29 based upon the stock trading at 8x our EV/5-year forward sales estimate. The price is a premium to small-cap peers trading at 1-2x and mid-cap peers at ~3x, justified by Relay’s platform technology for identifying selective agents against validation targets in oncology and near-term potential for platform validation. The analyst expects a marked reduction in high-grade hy
